Chronic thromboembolic pulmonary hypertension (CTEPH) is defined as symptomatic pulmonary hypertension (PH) due to non-resolving pulmonary emboli with a mean pulmonary arterial pressure (mPAP) of at least 25 mmHg, normal pulmonary arterial wedge pressure (PAWP; ≤15 mmHg), and perfusion defects that persist despite at least three months of anticoagulation.^[@bibr1-2045893217753122]^ It is assumed that PH develops due to an obstruction of at least 40--60% of the pulmonary vasculature,^[@bibr2-2045893217753122]^ but the role of the ensuing small-vessel pulmonary vascular remodeling remains unclear.^[@bibr3-2045893217753122],[@bibr4-2045893217753122]^ In addition, patients may be symptomatic with persistent pulmonary perfusion defects but no PH at rest. These patients are referred to as having chronic thromboembolic disease (CTED).^[@bibr5-2045893217753122]^

Surgical pulmonary endarterectomy (PEA) is the gold-standard treatment for CTEPH and is potentially curative.^[@bibr6-2045893217753122],[@bibr7-2045893217753122]^ Successful PEA has also been reported in patients with CTED, with perioperative mortality rates in the range of 0--0.9%.^[@bibr6-2045893217753122],[@bibr8-2045893217753122],[@bibr9-2045893217753122]^ Due to the low risk of the procedure, PEA surgery is the treatment of choice for operable, symptomatic patients with CTED.^[@bibr10-2045893217753122]^

Approximately one-third of all CTEPH patients are inoperable, however, mostly due to peripheral localization of pulmonary vascular obstructions.^[@bibr11-2045893217753122]^ These findings can probably be extrapolated to CTED patients. Currently, an increasing number of inoperable CTEPH patients are treated with balloon pulmonary angioplasty (BPA) in addition to targeted medical therapy.^[@bibr12-2045893217753122][@bibr13-2045893217753122][@bibr14-2045893217753122][@bibr15-2045893217753122][@bibr16-2045893217753122]--[@bibr17-2045893217753122]^ Hence, BPA may also be considered a treatment option for patients with inoperable CTED,^[@bibr11-2045893217753122]^ but data on the application of BPA in this population are lacking.

Here, we present the results of the first ten consecutive CTED patients who underwent BPA in Germany.

Methods {#sec1-2045893217753122}
=======

Patient selection {#sec2-2045893217753122}
-----------------

The two centers participating in this study (Hannover Medical School and the Kerckhoff Clinic, Bad Nauheim) hold weekly conferences of a multidisciplinary team consisting of experienced PEA surgeons, interventional radiologists, cardiologists and/or pulmonologists, and anesthesiologists, if required, to discuss particular cases.^[@bibr15-2045893217753122]^ CTED was diagnosed in symptomatic patients in at least World Health Organization (WHO) functional class (FC) II with pulmonary vascular lesions on computed tomography (CT) or PA angiography but with mPAP \< 25 mmHg at rest.^[@bibr5-2045893217753122]^ Patients were deemed inoperable based on a comprehensive assessment of imaging findings for peripherally located lesions that were not surgically approachable.^[@bibr18-2045893217753122]^ Per protocol, PH-targeted medication was not introduced before BPA.

All patients were informed in detail about the innovative nature of the procedure, including potential risks and benefits, and gave written consent to participate. The ethics committees of both institutions approved this prospective observational study.

Clinical assessment {#sec3-2045893217753122}
-------------------

As previously described,^[@bibr15-2045893217753122]^ all patients underwent standardized assessment before the first BPA and six months after the last intervention. Assessment included WHO FC, 6-min walking distance (6MWD) with Borg dyspnea index, pulmonary function testing including lung diffusion capacity for carbon monoxide (DLCO), serum levels of creatinine (with calculation of the estimated creatinine clearance) and of the N-terminal fragment of pro-brain natriuretic peptide (NT-proBNP), echocardiography, and right heart catheterization to determine right atrial pressure, pulmonary arterial pressures, PAWP, cardiac output (CO), cardiac index (CI), pulmonary vascular resistance (PVR), pulmonary arterial compliance (PAC), and mixed-venous oxygen saturation (SvO~2~). Cardiac magnetic resonance imaging (MRI) was used in the majority of patients to assess right ventricular (RV) function.

Balloon pulmonary angioplasty {#sec4-2045893217753122}
-----------------------------

BPA was performed as a staged procedure, with treatment of a limited number of pulmonary segments during each session. All procedures were performed in conscious patients with local anesthesia. The two centers used a common standard procedure:^[@bibr15-2045893217753122]^ a detailed plan for all interventions was established before the first session using angiographic und CT findings with the aim to treat all target lesions. Short-term web-like stenoses and long-segment obstructions in sub- and sub-subsegmental pulmonary arterial branches were considered as target lesions. Using a femoral or jugular access, a sheath was placed in the pulmonary artery and a guiding catheter was inserted into the target segmental arteries. The guidewire was then inserted into the target subsegmental branches, which were subsequently dilated by multiple balloon inflations. Based on the measured vessel diameter in CT and angiography slightly undersized balloons were used in all cases to avoid pulmonary arterial rupture. A final pulmonary angiogram documented the post-procedural morphologic result. In Hannover, selective C-Arm CT was also used to localize the target lesions.^[@bibr17-2045893217753122]^

Statistical analysis {#sec5-2045893217753122}
--------------------

All data for continuous variables are expressed as mean ± SD or as median and interquartile range (IQR), as appropriate. Categorical variables are reported as number and percentage. Continuous variables were compared using the Wilcoxon signed-rank test. Within-subject comparisons are made across repeated observations without correction for multiple comparisons. The CTED cohort data were distributed parametrically, as determined by the Kolmogorov--Smirnov test. All statistical tests were performed with SPSS software, version 22.0. A two-tailed *P* value \<0.05 was considered to be statistically significant.

Results {#sec6-2045893217753122}
=======

Baseline characteristics, effects of BPA, and procedures {#sec7-2045893217753122}
--------------------------------------------------------

Between August 2013 and June 2017, ten consecutive CTED patients were treated with BPA; three in Hannover and seven in Bad Nauheim. In the same time period, 33 CTED patients underwent PEA: four in Hannover and 29 in Bad Nauheim. The demographics and baseline characteristics of the patients who underwent BPA are depicted in [Table 1](#table1-2045893217753122){ref-type="table"}. The majority (9/10) were women. Follow-up ended in June 2017. The median duration between CTED diagnosis and first BPA was 16 (IQR = 4--35) months. Table 1.Characteristics of patients at time of inclusion.Last measurement before first interventionPatients (n (%))10 (100)Age (years) (median (IQR))69 (52--75)Female (n (%))9 (90)Body mass index (kg/m^2^) (median (IQR))28 (25--30)History of VTE (n (%))4 (40)Interval between CTED diagnosis and first BPA (months) (median (IQR))16 (4--35)*Pulmonary function* TLC (% pred)102 ± 9 FVC (% pred)96 ± 9 FEV~1~ (% pred)94 ± 10*PH therapy* Tadalafil (n (%))2 (20)*Anticoagulation* Vitamin K antagonist (n (%))3 (30) FXa inhibitor (n (%))7 (70)[^3][^4]

All patients were treated with anticoagulants at least three months before diagnosis. Despite mPAP \< 25 mmHg at the time of diagnosis, two patients received PH-targeted medical therapy with the phosphodiesterase 5 inhibitor sildenafil that was introduced at least three months before baseline assessment and kept unchanged during the study. Neither of these patients experienced improvement of their physical capacity under medication.

A total number of 35 interventions were performed: ten in Hannover and 25 in Bad Nauheim. In both centers, the median number of interventions per patient was four (range = 1--5). The median number of vessels targeted in all interventions was ten (range = 2--14). The median duration from first BPA to the 24-week follow-up assessment was 11 months (IQR = 9--14 months).

Treatment response {#sec8-2045893217753122}
------------------

The effects of BPA on hemodynamics, RV function, serum NT-proBNP, and exercise capacity are presented in [Table 2](#table2-2045893217753122){ref-type="table"}. The WHO FC improved in nine (90%) patients and remained unchanged in one (10%) patient. The 6MWD improved by an average of 31 m (about 8.5% from baseline) and this was accompanied by a reduction in the Borg dyspnea index. Hemodynamic assessment showed improvement in CO and SvO~2~, whereas mPAP was unchanged. There was a distinct decrease in PVR. Furthermore, PAC improved after BPA. DLCO and pO~2~ increased somewhat, but these changes were not statistically significant. RV function was unchanged on MRI before and after treatment. Table 2.Changes from baseline to week 24.nBaselinenWeek 24*P* value*Exercise capacity*WHO functional class (n (%))1010 I0 (0)4 (40)**0.004** II1 (10)5 (50) III9 (90)1 (10) IV0 (0)0 (0)6MWD (m)10365 ± 13910396 ± 1420.11Borg dyspnea scale (1--10)64.0 ± 1.061.8 ± 0.90.13*Hemodynamics and NT-proBNP* Right atrial pressure (mmHg)104 ± 2106 ± 30.12 mPAP (mmHg)1021 ± 21020 ± 30.74 systPAP (mmHg)1035 ± 61031 ± 70.31 diastPAP (mmHg)1010 ± 41011 ± 20.38 PAWP (mmHg)108 ± 31010 ± 2**0.02** DPG (mmHg)103 ± 3101 ± 10.20 TPG (mmHg)1012 ± 3109 ± 3**0.02** CO (L/min)104.3 ± 0.5104.5 ± 0.70.32 CI (L/min/m^2^)102.4 ± 0.3102.5 ± 0.40.38 PVR (dyn·s·cm^--5^)10234 ± 6810167 ± 40**0.004** PAC (mL/mmHg)103.2 ± 2.1104.1 ± 1.7**0.027** SvO~2~ (%)1065 ± 91069 ± 40.22 HR (bpm)1065 ± 91064 ± 80.66 NT-proBNP, ng/L (median (IQR))10144 (60--227)10109 (87--194)0.56*Blood gas analysis and pulmonary function* PaO~2~ (mmHg)768 ± 13771 ± 70.69 SaO~2~ (%)795 ± 3796 ± 10.94 PaCO~2~ (mmHg)734 ± 3735 ± 30.38 DLCO (% predicted)760 ± 11769 ± 180.19*MRI findings* LV-EF (%)668 ± 9669 ± 50.88 LV-SV (mL)676 ± 3676 ± 80.81 LV-EDV (mL)6114 ± 186112 ± 150.63 LV-ESV (mL)639 ± 15636 ± 100.44 RV-EF (%)655 ± 1655 ± 40.99 RV-SV (mL)675 ± 16668 ± 100.31 RV-EDV (mL)6135 ± 266125 ± 220.19 RV-ESV (mL)660 ± 10657 ± 140.38*Laboratory findings* Creatinine (µmol/L)1076 ± 25882 ± 230.99 eGFR (mL/min)881 ± 28867 ± 190.56[^5][^6]

Complications {#sec9-2045893217753122}
-------------

One procedure-related complication (Hannover, n = 0; Bad Nauheim, n = 1) occurred during the 35 interventions (2.9% of all interventions, 10% of the patients). This adverse event was caused by wire perforation of the pulmonary vasculature, resulting in parenchymal bleeding with mild hemoptysis; intervention was not required. All of the patients were alive at the end of the observation period.

Discussion {#sec10-2045893217753122}
==========

The observations presented here focus on the use of BPA in inoperable symptomatic CTED patients. We demonstrate individual improvements in exercise capacity (6MWD, WHO FC) and pulmonary hemodynamics (PVR, PAC). Furthermore, we show that BPA is feasible and relatively safe in this particular group of patients.

CTED was only described recently and there are only a few reports addressing treatment of these patients. In 13 years, only 42 out of 1019 patients undergoing PEA in a UK cohort were diagnosed with CTED.^[@bibr8-2045893217753122]^ PEA programs worldwide have shown excellent results, with functional improvements and low mortality rates.^[@bibr5-2045893217753122],[@bibr7-2045893217753122][@bibr8-2045893217753122]--[@bibr9-2045893217753122]^ Taboada et al. reported improvements in WHO FC, 6MWD, and PVR in 39 CTED patients before and six months after PEA: 20 patients were in WHO FC II and 22 in FC III before PEA; 16 patients were in WHO FC I, 21 in II, and two in FC III after PEA.^[@bibr8-2045893217753122]^ The 6MWD improved from 372 m to 413 m, and the PVR at rest decreased from 164 dynes to 128 dynes. These findings are in line with van Kan et al. who described changes in physical capacity and pulmonary hemodynamics in nine CTED patients one year after PEA: all patients were regrouped into WHO FC I after PEA and the 6MWD improved from 517 m to 548 m.^[@bibr19-2045893217753122]^ Therefore, PEA has become an accepted therapeutic strategy for symptomatic CTED patients, who potentially represent the lower border of the wide spectrum of CTEPH patients.^[@bibr10-2045893217753122]^ Based on experiences with CTEPH, however, it can be speculated that around one-third of all CTED patients are deemed inoperable. Previous data indicated that BPA may be feasible and effective in patients with lower mPAP.^[@bibr19-2045893217753122]^

Our preliminary results suggest that BPA may be an effective interventional treatment for patients with inoperable CTED, leading to improvements in WHO FC and pulmonary hemodynamics in the majority of the patients. The mean PVR reduction of 67 dynes\*s/cm^5^ is comparable to the results published for PEA procedures.^[@bibr7-2045893217753122][@bibr8-2045893217753122]--[@bibr9-2045893217753122]^ Furthermore, we observed a distinct improvement in PAC, which is believed to be one of the most important markers of prognosis in P(A)H patients.^[@bibr20-2045893217753122]^ However, its meaning in CTED remains unclear.

In our study, 6/10 patients increased their 6MWD and 7/10 patients had a lower NT-proBNP level 6 months after treatment. Overall, however, the changes in 6MWD and NT-proBNP were not statistically significant, potentially due to the low number of patients studied. Nevertheless, 9/10 patients had an improvement in WHO FC, a change that was significant for the cohort as a whole. MRI revealed that RV function was not affected by treatment; these findings before and after treatment. However, these findings could be explained by the absence of PH in this particular group of patients.

The small number of patients enrolled in this study is a major limitation that must be considered. In addition, there was no control group and long-term data are missing. The findings are nevertheless sufficient to demonstrate improvement in physical capacity and PVR. Furthermore, our data may provide a realistic perspective on the treatment of CTED patients in referral centers with an established surgical and interventional program for CTEPH.

Little is known about CTED and it is still being discussed whether it is an early stage in the development of CTEPH. PEA is an accepted surgical treatment for CTED patients, but there is no established treatment for inoperable patients. Our observation is the first to describe the effects of BPA in this particular group of patients. Improvements in physical capacity as well as pulmonary vascular resistance were achieved without severe complications. These data add important new information for the treatment of inoperable CTED patients. However, we have no data concerning prognostic implications of BPA in inoperable CTED patients. The development of a comprehensive therapeutic concept for CTED patients will require additional data and individualized decision-making based on multidisciplinary experience. Fig. 1.Individual effects of balloon pulmonary angioplasty on mPAP, PVR, functional capacity, 6MWD, and NT-proBNP. NT-proBNP, N-terminal pro-brain natriuretic peptide; PVR, pulmonary vascular resistance; PAC, pulmonary arterial compliance.
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